Enterosorbent for directed sorption of cholera exotoxin, dosage form of enterosorbent for directed sorption of cholera exotoxin

FIELD: pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, particularly, to production of the enterosorbent for directed sorption cholera exotoxin. Enterosorbent for directed sorption cholera Exotoxin, obtained by immobilization by method of adsorption antitoxic anticholeraic immunoglobulin G, recovered from blood serum of animals immunized with cholera toxin, on microparticle size 200–300 nm of pre-treated acid-soluble chitosan in ratio of 0.08–0.1:1. Solid dosage form of enterosorbent for directed sorption cholera exotoxin.

EFFECT: above solution enables to obtain a medicinal agent for directed sorption of cholera exotoxin and ensure reduction or complete neutralization of action of cholera exotoxin.

5 cl, 5 tbl, 6 ex



Same patents:

FIELD: medicine.

SUBSTANCE: method involves a combined administration of the preparations Enterosgel, Kudesan and Pantogam. Enterosgel is administered orally in the form of gel 30 minutes before meals in a dose of 1 teaspoon two times a day for 7 days. Kudesan is also administered orally during meals before noon in an age dose of: 10-16 drops (15-24 mg) in the children aged 5 through 7 years old, 16-20 drops (24-30 mg) in the children aged 8 through 10 years old, pre-dissolved in a small amount of boiled water or other beverage of room temperature, once a day in the course of 30 days. Pantogam is administered orally 15-20 minutes after meals in an age dose of: 500 mg 2 times a day in the children aged 5 through 7 years old, 500 mg 3 times a day in the children aged 8 through 10 years old in the course of 30 days.

EFFECT: complex administration regiment provides the effective correction of cognitive disorders in the given group of children by a synergetic detoxification, antioxidant and neuroprotective action of its components.

3 cl, 4 tbl

FIELD: chemistry.

SUBSTANCE: application of 5% water solution of sodium and potassium salts of humic acids, obtained from leonardite brown coal, in dose 10.0 mg/kg as membrane-protective preparation.

EFFECT: application of composition described above makes it possible to extend arsenal of membrane-protective preparations from low-toxic, cheap, available natural raw material.

2 dwg, 2 ex

FIELD: pharmacology.

SUBSTANCE: agent possessing detoxification activity, containing succinic acid, 10% ethanol extract of propolis, polyethylene glycol 400, polyethylene glycol 1500, polyethylene glycol 4000, Cremophor CO-40, Tween-80 and purified water in certain proportions.

EFFECT: agent possesses the detoxification action, the uniform release of the active substances and the pronounced prolonged action.

2 cl, 4 dwg, 4 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to radiation and experimental biology, biotechnology and medicine, namely to means of radiological protection and to stimulators of colony formation of stem cells. Invention can be used in research and clinical practice for protection of living organisms in case of exposure to ionising radiation, in emergency and military medicine, in case of emergency situations as means for protection against radiation injury. Claimed is application of preparation gamma-plant as radioprotector with colony-stimulating properties for increasing survival and improving state of organisms, subjected to irradiation. Gamma-plant is non-toxic polysaccharide of vegetable origin, registered by Ministry of Health of the Russian Federation and allowed for medical application; Gamma-plant is included into Russian Pharmacopoeia in section FG-9 "non-narcotic analgesics".

EFFECT: invention makes it possible to increase efficiency of colony formation of stem cells in spleen 2,0-2,3 times, increases survival of experimental animals to 95% with coefficient of dose reduction factor DRF, equal 2-2,2.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.

EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.

FIELD: medicine.

SUBSTANCE: first, Fraxiparine is inhaled for 5-10 minutes. A dialysis solution for peritoneal dialysis containing extranyl is administered into the abdominal cavity 1-1.5 hours later through a catheter. The solution additionally contains: albumin in the concentration of 35-40 g/l, heparin in the concentration of 500-750 Unit/l and papaverine in the concentration of 50-100 mg/l. Every 6-8 hours after the beginning of exposure of the dialysis solution in the abdominal cavity, the Fraxiparine inhalations are repeated. The time of a single exposure of the dialysis solution in the abdominal cavity makes 12-18 hours.

EFFECT: method provides effective body detoxification in the given category of patients by providing a high toxin clearance owing to a continuous high osmotic concentration of the solution and the dilatation of pre-capillary peritoneal arterioles, prevented inspissation of the albumin solution to the colloidal state and its inactivation that reduces a rate of the dialysis solution exchanges.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an immunomodulatory composition for injection into a mammal. The immunomodulatory composition for injection into a mammal containing a hydrolysate prepared by acid and/or enzymatic hydrolysis of one or more bioresources specified in a group consisting of bivalve molluscs, annelids, leeches, and water taken in certain proportions. A method for preparing the immunomodulatory composition for injection into a mammal. A method of treating a pathological condition in a mammal in need thereof involving the injections of the immunomodulatory composition into the above mammal. Using the composition for normalising metabolism into the mammal in need thereof.

EFFECT: composition enables extending the range of products with immunomodulatory activity for injections.

19 cl, 7 tbl, 7 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of calves with Simuliidotoxicosis is that 40% solution of urotropine is administered intravenously to calves at a dose of 1.5 ml per 10 kg of animal body weight.

EFFECT: improvement of efficiency of the method.

FIELD: medicine.

SUBSTANCE: group of inventions relates to veterinary and medicine, in particular to obtaining and application of biopreparations for immunotherapy of ecopathologies. The group of inventions includes obtaining a protein antigen from a mixture of anatoxins from three enteropathogenic virulent strains of a pathogen of escherichiosis of calves E.coli No. 378, 379, 380 by their growing on Hottinger medium with further addition of 0.4-0.5% formalin, following thermostating for 10-12 days and cooling the mixture of anatoxins with a sterile solution of aluminium hydroxide, after that obtaining radioantigen from E.coli "PL-6" by growing cultures on a meat infusion agar with further washing away a biomass by a physiological solution and irradiation of the obtained suspension with a concentration of 1.2·1010 m.c./cm3 on a gamma-installation in a dose of 140-150 Gr with following thermostating and extraction of radiotoxin with 70% acidified with 0.05% hydrochloric acid to pH 5.5 ethanol, following evaporation of the exractant to the initial volume, after that, obtaining protein-cadmium radioantigen first by preliminary dechlorination of cadmium chloride, obtaining cadmium hydroxide, addition into the obtained 2.7% solution of the antigen of 0.77% solution of cadmium hydroxide in a ratio of 1:1 with following thermostating at a temperature of 37°C for 30 minutes, evaporation and dissolution of the residue to 12.8% concentration, further obtaining protein-cadmium radioantigen by an addition of 1.2% solution of a mixture of three anatoxins of E.coli and 12.8% solution of cadmium radioantigen in a ratio of 1:9, conjugation of components at room temperature for 8-10 hours, standardisation by a dry substance to 10% concentration and pouring into vials, and storage at a temperature of 4-6°C. The group of inventions also relates to a method of treating radiation, chemical and/or bacteriological damage to an organism by introduction of 10% solution of complex protein-cadmium radioantigen.

EFFECT: application of the group of inventions is effective in treatment of radiation, chemical and/or biological damage.

4 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and particularly to preparations for a therapy of oncological diseases, treatment of allergy, prevention and health improvement. The invention represents a method for preparing fraction 4 (ADP-f4) and fraction (ADP-f5) adaptogenic Dorogov's preparations, characterised by the fact that a primary product is a fraction 2 antiseptic Dorogov's stimulator (ADP-f2) to be thermally treated.

EFFECT: implementing the given invention provides the more effective prevention and eliciting anti-stress reactions for the purpose of improving the functional state of organism and increasing a resistance in an activation therapy.

2 tbl

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to a method of analysing ex-vivo if a patient suffering a cancer is expected to respond therapeutically to a method of treating. To this purpose, a biological sample specified in a group consisting of total blood, plasma or serum samples is taken from the patient. The levels IL10 and IFNγ are measured in the above biological sample; the levels are determined with using the respective IL10 and INFγ specific antibodies. The IL10/IFNγ ratio is derived and compared to a threshold. If the IL10/IFNγ ratio of less than 4 shows that the patient is expected to develop the preventive or therapeutic response to the immunogenic composition. The group of inventions also refers to using IL10 and INFγ as biomarkers and a kit for analysing the above method.

EFFECT: using the given method enables predicting the sensitivity of the patient suffering cancer to the therapeutic treatment, as well as obtaining an algorithm for treatment modification for improving the patient's response to the treatment.

12 cl, 2 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and diagnosis of infectious diseases, namely brucellosis. A method for making brucellosis diagnostic serum involves the single administration of a mixed antigen (100 billion cell of killed culture of the strain B.abortus 19) with the MONTANIDE™ ISA 61 VG adjuvant. -On the 18-20th day, the blood sample is taken, whereas the blood is taken twice from each producer animal at 16-20 ml of the blood per 1 kg of body weight, or the process bloodletting is performed on the 24-30th post-hyperimmunisation day. The serum taken from each producer animal is poured separately into sterile bottles and preserved by adding 4% dry boric acid, heated on a water bath at 54-56°C for 40 minutes while stirring continuously, then placed for 10 days into a fridge at a temperature of 2-8°C. The blood sample is then checked for sterility, activity and specificity. The serum is expected to be sterile and have an agglutination titre not less than 1,000 International Units, and a complement binding titre of not less than 1:20.

EFFECT: technical effect is reducing the labour intensity of the process and the epidemic safety.

2 tbl, 2 ex

FIELD: biotechnologies.

SUBSTANCE: invention describes a composition for induction of immune response against P. gingivalis, which contains an effective amount of one of the above chimeric or hybrid proteins, a prophylaxis method of a state or a disease related to P. Gingivalis, and a method for reduction of incidence or severity of the state or disease related to P. gingivalis with their application. Besides, the invention describes use of the above chimeric or hybrid proteins for determination of antibodies to P. Gingivalis in a biological specimen.

EFFECT: invention allows effective induction of immune response against the specified etiologic agent.

16 cl, 7 dwg, 4 tbl, 22 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science, namely veterinary epizootiology and immunology. The method implies as follows. The producing pigs are hyperimmunised intramuscularly in various points using monovalent inactivated porcine circovirus infection (PCVI), reproductive and respiratory syndrome (PRRS) and hemophilosis vaccines in graded doses every 7 days; that is combined with administering the preparation Gamavit for additional immunogenesis stimulation.

EFFECT: higher preventive effect and reducing length of treating of associated viral-bacterial diseases in weaned pigs due to maintaining high serum protective antibody titers to circovirus infection min 1:25600, to reproductive and respiratory syndrome min 1:12800 (in ELISA), to hemophilosis min 1:512 (in agglutination reaction).

3 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: there are presented antibodies specifically binding the lipid-associated antigen of M.hominis with the characterised amino acid and nucleotide sequences, as well as a method of treating a Mycoplasma M.hominis infection involving administering to said mammal a therapeutically effective amount of the nanoantibodies.

EFFECT: invention can find further application in treating the mycoplasma infection.

4 cl, 2 tbl, 6 ex, 5 dwg

FIELD: medicine.

SUBSTANCE: invention discloses a purified and/recombinant antigen polypeptide possessing toxin activity, recovered from Clostridium perfringens with specified amino acid sequence. The invention discloses the recovered or recombinant polynucleotide coding such polypeptide, an expression vector and a host cell expressing the polypeptide. The invention discloses a method for preparing the polypeptide, an antibody specifically bound with the polypeptide, immunogenic compositions and vaccines containing the given polypeptide or a polynucleotide thereby providing a specifically immune response to the polypeptide. There are disclosed a method for inducing the immune response, a method of determining the fact whether an individual has been exposed to a pathogen (versions), a method of screening, an agonist or an antagonist modulating activity of the polypeptide, a method of animal vaccination, e.g. hens for inducing active immunity, as well as passive immunity in hen off-springs which becomes less sensitive to clostridial diseases. What is disclosed is a transgenic plant containing the exogenous polynucleotide coding the polypeptide under the invention, applicable for animal feeding.

EFFECT: polypeptide is used as an ingredient of a forage or a beverage for preventing a disease caused by bacteria expressing the polypeptide under the invention.

39 cl, 8 dwg, 6 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: polypeptide (versions) immunogenic with respect to meningococcal infections contains: an amino acid sequence at least 90 % identical to a sequence presented in the description (SEQ ID NO: 32), or said amino acid sequence, or a fragment of 80 sequenced amino acids of said sequence. What is described is an antibody which contacts with the polypeptide under the invention and which may be used as a drug. What is described is nucleic acid of the preset structure which codes the polypeptide or its versions and which may be used for treating or preventing a disease and/or an infection caused by Neisseria meningitides. The invention provides additional polypeptides applicable in advanced vaccines for preventing and/or treating meningococcal meningitis. The peptides can also find application in diagnosing of the disease and as targets of antibiotics.

EFFECT: higher clinical effectiveness for meningococcal meningitis.

19 cl, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of veterinary virology. Serum contains antibodies in titres: to rotavirus, virus of mucosa diarrhea-disease - not less than 1:1600 (in EIA), virus of infectious rhinotracheitis - not less than 1:16 (in NR), coronavirus and parainfluenz-3 virus not less than 1:152 (in IHAR). Serum is obtained by hyperiimunisation of oxen-producers with polyvalent viral antibody, containing mixture of culture viral suspensions of cattle rotavirus with titre 7.0-8.0 Ig TCD 50/ml, cattle coronavirus with titre 6.0-7.0 Ig TCD 50/ml, virus of cattle infectious rhinotracheitis with titre 7.5-8.0 Ig TCD 50/ml, parainfluenza-3 virus with titre 7.5-8 Ig TCD 50/ml, virus of mucosa diarrhea-disease with titre 4.5-9.5 Ig TCD 50/ml. With preventive purpose serum is introduced to a calf not later than 2-3 hours after birth and re-introduced after 24 hours, subcutaneously into several points in dose 1.0 cm3 per 1 kg of animal weight. In case if disease symptoms appear, serum is introduced to a calf in therapeutic doses 1.5 cm3 per 1 kg of weight, in combination with antibiotics subcutaneously in several points 1 time per day 2-3 days running.

EFFECT: group of inventions provides reliable passive immunity in extremely short terms and reduces the number of vaccinations.

2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to preparing diagnostic products. The method is implemented by intratesticular infections of rabbits producers of 3.0-3.5 kg with pathogenic Nichols strain T. Pallidum pallidum. 7-8 days after the infection, the animals are additionally twice intravenously immunised with purified treponema proteins ("ОПТ"-antigen) recovered from "КСТ"-antigen of cultural Treponema Palladium in dosage 0.023 g, every 7-8 days. It is followed with exsanguination 30 days after the infection. The prepared serums are analysed for anticardiolipin antibodies titre in quantitative cardiolipin antigen microprecipitation test.

EFFECT: method allows increasing anticardiolipin antibodies titre, standardising a procedure of quantitative cardiolipin microprecipitation test for syphilis, and halving the findings analysis time.

2 ex

FIELD: medicine.

SUBSTANCE: substance of the invention involves sterile liquid or dry specifically active F(ab')2-fragments of anti-anthrax antibodies containing (35±5) mg·cm3 of protein and at least 96% of F(ab')2-fragments of antibodies recovered from liquid equine anti-anthrax immunoglobulin prepared of blood serum of horses preliminary immunised with strains B anthracis "СТИ"-1 and Ichtiman, and also a anthrax toxin produced by the Kohn's spirit deposition method.

EFFECT: lower reactogenicity and improved immunogenicity.

1 tbl

FIELD: medicine.

SUBSTANCE: described is a method of obtaining a composite chitosan-based material, which contains aspartic or glutamine amino acids in a quantity from 2 to 5 wt %, as well as calcium phosphates with a ratio of Ca/P from 1.0 to 1.67. The method consists in barbotage through a suspension of calcium phosphates, obtained in situ in a solution of chitosan and aspartic or glutamic acid, with the following lyophilic drying of the foamed products. Porous matrices can be applied in dentistry, maxillofacial surgery, osteoplastic surgery as implants in the treatment of bone tissue defects.

EFFECT: obtained samples are characterised by a uniform porous structure with the simultaneous reduction of calcium phosphate dimensions to a nano-level with the reduction of the number of material obtaining operations.

2 dwg, 5 ex